Veru Q2 net loss $2.7M; PLATEAU trial interim analysis expected Q1 2027

VERU INC.

Net loss $2.7M ($0.12/sh) vs $7.9M ($0.54) in Q2 2025; operating loss $7.2M.
Cash, equivalents & restricted cash $27.6M as of Mar 31, 2026, up from $15.8M Sep 30, 2025.
Phase 2b PLATEAU trial actively enrolling; interim analysis on lean/fat mass expected Q1 2027.
R&D expenses $3.1M (down from $3.9M); G&A $4.1M (down from $5.2M) vs year-ago quarter.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERU INC. reported six months ended March 31, 2026 results: net income $8.1 million, or $0.37 per share, EPS $0.37 per share.

Period: six months ended March 31, 2026
Net income: $8.1 million, or $0.37 per share
EPS: $0.37 per share
Result: reported results

Exact text from the filing

Net loss decreased to $8.1 million, or $0.37 per share, compared to $16.8 million, or $1.15 per share

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

VERU INC. reported fiscal 2026 second quarter ended March 31, 2026 results: net income $2.7 million, or $0.12 per share, EPS $0.12 per share.

Period: fiscal 2026 second quarter ended March 31, 2026
Net income: $2.7 million, or $0.12 per share
EPS: $0.12 per share
Result: reported results

Exact text from the filing

Net loss decreased to $2.7 million, or $0.12 per share, compared to $7.9 million, or $0.54 per share

View on SEC.gov

20 earnings releases filed in the last 30 days. Browse all earnings releases →

VERU INC. filing history →

Source: SEC EDGAR

accession 0001193125-26-220569

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.